Research Article
Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients
Table 2
Demographic and clinical characteristics at baseline.
| | Characteristics | Overall subjects |
| | Recipient age (years), median (range) | 38 (23–68) | | Gender, (%) | | | Male | 23 (51.1%) | | Female | 22 (48.9%) | | Time to initiation of therapy after transplantation (months), median (range) | 36 (1–120) | | Patients detected HCV positive, (%) | | | Before transplantation | 18 (40%) | | After transplantation | 27 (60%) | | Diabetes mellitus, (%) | 4 (8.9%) | | New onset diabetes after transplantation, (%) | 8 (17.8%) | | HCV genotype, (%) | | | 1 | 15/45 (33.3%) | | 3 | 30/45 (66.7%) | | 2, 4, 6 | Nil | | METAVIR fibrosis stage, (%) | | | F0–F2 | 38 (84.4%) | | F3-F4 | 7 (15.6%) | | Hepatic decompensation | Nil | | HCV viral load (IU/ml), median (range) | 542648 (1189–55028534) | | Serum creatinine at treatment initiation (mg/dl), median (range) | 1.22 (0.66–2.0) | | Estimated GFR (ml/min/1.73 m2), median (range) | 57 (30–118) | | Baseline immunosuppression regimen (in combination with Mycophenolate Mofetil/Azathioprine and Prednisolone), (%) | | | Tacrolimus based | 39 (86.7%) | | Cyclosporine based | 4 (8.9%) | | Everolimus based | 2 (4.4%) |
|
|
